Compare SSYS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSYS | CDNA |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.8M | 1.0B |
| IPO Year | 2012 | 2007 |
| Metric | SSYS | CDNA |
|---|---|---|
| Price | $8.56 | $17.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $12.33 | ★ $27.33 |
| AVG Volume (30 Days) | ★ 865.9K | 591.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $4.69 | $15.37 |
| Revenue Next Year | $6.09 | $11.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $8.12 | $10.96 |
| 52 Week High | $12.78 | $21.49 |
| Indicator | SSYS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 37.96 |
| Support Level | $8.34 | $16.74 |
| Resistance Level | $11.43 | $18.02 |
| Average True Range (ATR) | 0.47 | 0.85 |
| MACD | -0.20 | -0.13 |
| Stochastic Oscillator | 11.74 | 23.20 |
Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.